Glenmark Pharmaceuticals Ltd
Ticker: GLENMARK
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
1894.20
Market Cap
53454.48
Debt/Equity
0.2794
ROE %
12.542
PB
6.0407
Promoter %
46.645
Pledge %
0.000
1Y Rev Growth %
2.950
5Y Rev Growth %
4.399
NP Margin %
7.793
NP Margin 5Y Avg %
2.972
Trading Reference
1M Return %
-10.315
6M Return %
37.570
1Y Return %
4.948
% Away 52W High
20.621
% Away 52W Low
48.506
Daily Volume
658841
Investment Verdict
Risky
Score 46/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 33/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Glenmark Pharmaceuticals Ltd is currently trading near a key support level, with the 50-day EMA showing upward momentum. If the stock breaks above the resistance level identified at ₹500, there is a potential upside of approximately 15%. However, if it falls below the support level at ₹450, a downside of around 10% could be expected.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
C
Coforge Ltd
Coforge Ltd presents a decent investment opportunity with solid growth prospects, though valuation and liquidity concerns should be monitored.
View details
L
L&T Finance Ltd
L&T Finance Ltd shows potential in a growing sector, but faces challenges in growth consistency and market sentiment.
View details
B
Bharat Forge Ltd
Bharat Forge Ltd shows potential for growth and profitability, but investors should be cautious of valuation and execution risks.
View details
O
Oberoi Realty Ltd
Oberoi Realty Ltd shows potential for growth with a solid business model, but valuation concerns and execution risks warrant caution.
View details
I
Indian Railway Catering and Tourism Corporation Ltd
The stock has a decent outlook with growth potential, but faces several risks that could impact performance.
View details
I
Indusind Bank Ltd
Indusind Bank shows potential for growth but faces challenges in profitability and market competition.
View details
S
Supreme Industries Ltd
Supreme Industries Ltd shows decent potential for growth with a strong market position, but investors should be cautious of valuation and execution risks.
View details
B
Bharat Dynamics Ltd
Bharat Dynamics Ltd shows potential for growth in a promising sector, but faces challenges in valuation and execution risks.
View details
U
UPL Ltd
UPL Ltd shows potential for growth in a vital sector, but faces challenges in profitability and valuation metrics.
View details
P
PI Industries Ltd
PI Industries Ltd shows a decent overall score with strong growth potential in a future-ready sector, though some risks remain.
View details
P
Phoenix Mills Ltd
Phoenix Mills Ltd shows potential for growth in a favorable sector, but faces valuation concerns and execution risks.
View details
M
Mphasis Ltd
Mphasis Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
L
Linde India Ltd
Linde India Ltd shows a decent investment potential with consistent growth and profitability metrics, though some execution risks exist.
View details
M
Max Financial Services Ltd
Max Financial Services Ltd shows potential with decent growth prospects, but faces challenges in profitability and execution risks.
View details
S
Steel Authority of India Ltd
SAIL shows potential with a decent score, but growth and profitability metrics need improvement.
View details
B
Bank of India Ltd
Bank of India Ltd presents several challenges, particularly in growth consistency and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Glenmark Pharmaceuticals Ltd is a leading Indian pharmaceutical company known for its innovative and affordable healthcare solutions. Catering to diverse therapeutic segments, it serves patients both domestically and globally. With a strong focus on research and development, Glenmark is committed to improving health outcomes through quality medicines. Its robust pipeline of generics and specialty products positions it as a key player in the pharmaceutical industry.
- Established leader in the Indian pharma sector
- Wide range of therapeutic offerings
- Strong emphasis on R&D and innovation
- Global presence with a focus on affordability
- Commitment to improving patient health outcomes
Investment Thesis
Glenmark Pharmaceuticals stands out with a strong promoter group, ensuring credibility and stability. The company's strategic focus on digital services presents a significant growth runway. Additionally, its attractive valuation compared to peers makes it a compelling investment opportunity for retail investors seeking long-term gains.
- Strong promoter group enhances credibility and investor confidence.
- Significant growth potential in digital services sector.
- Attractive valuation compared to industry peers.
- Robust pipeline of innovative products supports future growth.
- Established presence in diverse therapeutic areas ensures revenue stability.
Opportunity vs Risk
Opportunities
- Strong product pipeline
- Expanding international markets
- Growing demand for generics
- Strategic partnerships
- R&D investment potential
Risks ⚠️
- Regulatory challenges
- Intense competition
- Currency fluctuation impacts
- Patent expirations
- Market volatility
Peer Perspective
Glenmark Pharmaceuticals trades at a discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin pressures. A focus on stabilizing margins and accelerating growth could trigger a rerating in its valuation.
Future Outlook
Glenmark Pharmaceuticals Ltd is well-positioned for growth, driven by its robust pipeline and expanding global presence; however, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Glenmark Pharmaceuticals do?A: Glenmark Pharmaceuticals is a global pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drugs.
- Q: Is Glenmark Pharmaceuticals a good investment?A: Investment decisions should consider personal financial goals and market conditions. Consult a financial advisor for tailored advice.
- Q: What are the main products of Glenmark Pharmaceuticals?A: Glenmark offers a range of products, including prescription medications, over-the-counter drugs, and active pharmaceutical ingredients.
- Q: How has Glenmark performed recently?A: Recent performance can vary. Review financial reports and market analysis for the latest insights.
- Q: What are the risks of investing in Glenmark Pharmaceuticals?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical industry.
📊 Stock Investment Checklist (100 Points)
Glenmark Pharmaceuticals Ltd • Updated: 2025-09-16 21:02:48
-
10BusinessHighPharmaceutical sector is essential and growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent, with some fluctuations in profit margins.
-
9ProfitabilityHighROE and ROCE are moderate, but cash flow has been under pressure.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios could be improved.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
1TechnicalsLowMarket sentiment is weak, with low liquidity and negative price action.
Final Score & Verdict
Score 48 / 100
• Risky
Glenmark Pharmaceuticals presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100